A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Trial Profile

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs INCB 50465 (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms CITADEL-203
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 18 Nov 2017 Study protocol has been amended for this trial and multiple fields in the profile are changed.Comparator drug Idelalisib has been removed from the study hence treatment arms changed from 3 to 2.Study title and purpose also changed. Study design changed from randomized to non-randomized. Patient number changed from 180 to 100.
    • 18 Nov 2017 Planned End Date changed from 1 Dec 2019 to 1 Jan 2020.
    • 18 Nov 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top